Replace with audited BioFormBench-Real (49 rows, sourced) and new BioFormBench-Marketed (165 rows, 80 sequenced antibodies); remove dev scaffolding and unsourced placeholder data
Browse files- README.md +203 -230
- bioformbench_extracted_real_20260903.csv +0 -9
- bioformbench_extracted_real_batch2_20260903.csv +0 -17
- bioformbench_extracted_real_batch3_20260903.csv +0 -15
- bioformbench_extracted_real_batch4_20260903.csv +0 -4
- bioformbench_marketed.csv +0 -0
- bioformbench_seed.csv → bioformbench_real.csv +27 -45
- bioformbench_seed_backup_20260903.csv +0 -27
- synthetic_generator.py +0 -363
- synthetic_training_data.csv +0 -3
- synthetic_training_data.parquet +0 -3
README.md
CHANGED
|
@@ -1,230 +1,203 @@
|
|
| 1 |
-
---
|
| 2 |
-
dataset_info:
|
| 3 |
-
|
| 4 |
-
|
| 5 |
-
|
| 6 |
-
|
| 7 |
-
|
| 8 |
-
|
| 9 |
-
|
| 10 |
-
|
| 11 |
-
|
| 12 |
-
|
| 13 |
-
|
| 14 |
-
|
| 15 |
-
|
| 16 |
-
|
| 17 |
-
|
| 18 |
-
|
| 19 |
-
|
| 20 |
-
|
| 21 |
-
|
| 22 |
-
|
| 23 |
-
|
| 24 |
-
|
| 25 |
-
|
| 26 |
-
|
| 27 |
-
|
| 28 |
-
|
| 29 |
-
|
| 30 |
-
|
| 31 |
-
|
| 32 |
-
|
| 33 |
-
|
| 34 |
-
|
| 35 |
-
|
| 36 |
-
|
| 37 |
-
|
| 38 |
-
|
| 39 |
-
|
| 40 |
-
|
| 41 |
-
|
| 42 |
-
|
| 43 |
-
|
| 44 |
-
|
| 45 |
-
|
| 46 |
-
|
| 47 |
-
|
| 48 |
-
|
| 49 |
-
|
| 50 |
-
|
| 51 |
-
|
| 52 |
-
|
| 53 |
-
|
| 54 |
-
-
|
| 55 |
-
|
| 56 |
-
|
| 57 |
-
|
| 58 |
-
|
| 59 |
-
|
| 60 |
-
|
| 61 |
-
|
| 62 |
-
|
| 63 |
-
|
| 64 |
-
|
| 65 |
-
|
| 66 |
-
|
| 67 |
-
|
| 68 |
-
|
| 69 |
-
|
| 70 |
-
|
| 71 |
-
|
| 72 |
-
|
| 73 |
-
|
| 74 |
-
|
| 75 |
-
|
| 76 |
-
|
| 77 |
-
|
| 78 |
-
|
| 79 |
-
|
| 80 |
-
|
| 81 |
-
|
| 82 |
-
|
| 83 |
-
|
| 84 |
-
|
| 85 |
-
|
| 86 |
-
|
| 87 |
-
|
| 88 |
-
|
| 89 |
-
|
| 90 |
-
|
| 91 |
-
|
| 92 |
-
|
| 93 |
-
|
| 94 |
-
|
| 95 |
-
|
| 96 |
-
|
| 97 |
-
|
| 98 |
-
|
| 99 |
-
|
| 100 |
-
|
| 101 |
-
|
| 102 |
-
|
| 103 |
-
|
| 104 |
-
|
| 105 |
-
|
| 106 |
-
|
| 107 |
-
|
| 108 |
-
|
| 109 |
-
|
| 110 |
-
|
| 111 |
-
|
| 112 |
-
|
| 113 |
-
|
| 114 |
-
|
| 115 |
-
|
| 116 |
-
|
| 117 |
-
|
| 118 |
-
|
| 119 |
-
|
| 120 |
-
|
| 121 |
-
|
| 122 |
-
|
| 123 |
-
|
| 124 |
-
|
| 125 |
-
|
| 126 |
-
-
|
| 127 |
-
|
| 128 |
-
|
| 129 |
-
-
|
| 130 |
-
|
| 131 |
-
|
| 132 |
-
|
| 133 |
-
|
| 134 |
-
-
|
| 135 |
-
-
|
| 136 |
-
|
| 137 |
-
##
|
| 138 |
-
|
| 139 |
-
|
| 140 |
-
|
| 141 |
-
|
| 142 |
-
|
| 143 |
-
|
| 144 |
-
|
| 145 |
-
|
| 146 |
-
|
| 147 |
-
|
| 148 |
-
|
| 149 |
-
|
| 150 |
-
|
| 151 |
-
|
| 152 |
-
|
| 153 |
-
-
|
| 154 |
-
-
|
| 155 |
-
|
| 156 |
-
|
| 157 |
-
|
| 158 |
-
|
| 159 |
-
|
| 160 |
-
|
| 161 |
-
|
| 162 |
-
|
| 163 |
-
|
| 164 |
-
|
| 165 |
-
|
| 166 |
-
|
| 167 |
-
|
| 168 |
-
|
| 169 |
-
-
|
| 170 |
-
|
| 171 |
-
|
| 172 |
-
|
| 173 |
-
|
| 174 |
-
|
| 175 |
-
|
| 176 |
-
|
| 177 |
-
|
| 178 |
-
|
| 179 |
-
|
| 180 |
-
|
| 181 |
-
|
| 182 |
-
|
| 183 |
-
|
| 184 |
-
|
| 185 |
-
|
| 186 |
-
|
| 187 |
-
|
| 188 |
-
|
| 189 |
-
|
| 190 |
-
|
| 191 |
-
|
| 192 |
-
|
| 193 |
-
|
| 194 |
-
|
| 195 |
-
|
| 196 |
-
|
| 197 |
-
#
|
| 198 |
-
|
| 199 |
-
|
| 200 |
-
|
| 201 |
-
|
| 202 |
-
|
| 203 |
-
|
| 204 |
-
git clone https://github.com/Maheshbonthada/bioform-lm.git
|
| 205 |
-
cd bioform-lm
|
| 206 |
-
# See data/bioformbench_extracted_real_*.csv
|
| 207 |
-
```
|
| 208 |
-
|
| 209 |
-
## Future Expansion
|
| 210 |
-
|
| 211 |
-
**Planned scalings:**
|
| 212 |
-
- Target: 200+ formulations across 8-10 proteins
|
| 213 |
-
- Systematic literature mining of supplementary materials
|
| 214 |
-
- Inclusion of immunogenicity + manufacturability data
|
| 215 |
-
- Temporal stability curves (not just endpoint measurements)
|
| 216 |
-
|
| 217 |
-
## Contact
|
| 218 |
-
|
| 219 |
-
**Dataset Curator:** Bonthada Sravan Kumar
|
| 220 |
-
Email: sravansaijohn@gmail.com
|
| 221 |
-
Questions: Open issue on GitHub (Maheshbonthada/bioform-lm)
|
| 222 |
-
|
| 223 |
-
## License
|
| 224 |
-
|
| 225 |
-
**CC-BY-4.0** - Attribution required for academic/commercial use
|
| 226 |
-
|
| 227 |
-
---
|
| 228 |
-
|
| 229 |
-
**Last Updated:** September 7, 2026
|
| 230 |
-
**Status:** ✅ Released | 🔄 Accepting contributions via GitHub
|
|
|
|
| 1 |
+
---
|
| 2 |
+
dataset_info:
|
| 3 |
+
- config_name: bioformbench_real
|
| 4 |
+
features:
|
| 5 |
+
- name: protein_id
|
| 6 |
+
dtype: string
|
| 7 |
+
description: Protein identifier (traceable to source_id)
|
| 8 |
+
- name: protein_mw_kda
|
| 9 |
+
dtype: float32
|
| 10 |
+
description: Molecular weight (kDa)
|
| 11 |
+
- name: protein_pi
|
| 12 |
+
dtype: float32
|
| 13 |
+
description: Isoelectric point
|
| 14 |
+
- name: protein_tm_baseline_c
|
| 15 |
+
dtype: float32
|
| 16 |
+
description: Baseline melting temperature (C), no stabilizer
|
| 17 |
+
- name: buffer_species
|
| 18 |
+
dtype: string
|
| 19 |
+
description: Buffer chemical
|
| 20 |
+
- name: buffer_conc_mm
|
| 21 |
+
dtype: float32
|
| 22 |
+
description: Buffer concentration (mM)
|
| 23 |
+
- name: ph
|
| 24 |
+
dtype: float32
|
| 25 |
+
description: Formulation pH
|
| 26 |
+
- name: ionic_strength_mm
|
| 27 |
+
dtype: float32
|
| 28 |
+
description: Ionic strength (mM)
|
| 29 |
+
- name: osmolarity_mosm_kg
|
| 30 |
+
dtype: float32
|
| 31 |
+
description: Osmolarity (mOsm/kg)
|
| 32 |
+
- name: stabilizers_json
|
| 33 |
+
dtype: string
|
| 34 |
+
description: JSON dict of stabilizer name to concentration
|
| 35 |
+
- name: temperature_c
|
| 36 |
+
dtype: float32
|
| 37 |
+
description: Storage/measurement temperature (C)
|
| 38 |
+
- name: stability_score
|
| 39 |
+
dtype: float32
|
| 40 |
+
description: Normalized stability outcome, 0-1, higher = more stable
|
| 41 |
+
- name: measured_aggregation_percent
|
| 42 |
+
dtype: float32
|
| 43 |
+
description: SEC percent aggregation, where reported
|
| 44 |
+
- name: measured_tm_shift_c
|
| 45 |
+
dtype: float32
|
| 46 |
+
description: DSF Tm shift versus baseline, where reported
|
| 47 |
+
- name: source_title
|
| 48 |
+
dtype: string
|
| 49 |
+
description: Title of the primary literature source (required; unsourced rows are excluded, see Data Integrity)
|
| 50 |
+
- name: source_id
|
| 51 |
+
dtype: string
|
| 52 |
+
description: PubMed Central identifier of the primary source
|
| 53 |
+
splits:
|
| 54 |
+
- name: full
|
| 55 |
+
num_examples: 49
|
| 56 |
+
- config_name: bioformbench_marketed
|
| 57 |
+
features:
|
| 58 |
+
- name: inn
|
| 59 |
+
dtype: string
|
| 60 |
+
description: Antibody International Nonproprietary Name
|
| 61 |
+
- name: title
|
| 62 |
+
dtype: string
|
| 63 |
+
description: FDA label title (product name, manufacturer)
|
| 64 |
+
- name: ph
|
| 65 |
+
dtype: float32
|
| 66 |
+
description: Formulation pH parsed from the label
|
| 67 |
+
- name: buffer_species
|
| 68 |
+
dtype: string
|
| 69 |
+
description: Buffer chemical, where fully resolved
|
| 70 |
+
- name: buffer_conc_mm
|
| 71 |
+
dtype: float32
|
| 72 |
+
description: Buffer concentration (mM), where fully resolved
|
| 73 |
+
- name: surfactant
|
| 74 |
+
dtype: string
|
| 75 |
+
description: Surfactant identity, where present
|
| 76 |
+
- name: fv_pi
|
| 77 |
+
dtype: float32
|
| 78 |
+
description: Isoelectric point computed from the VH+VL Fv sequence (Biopython ProtParam)
|
| 79 |
+
- name: fv_mw_kda
|
| 80 |
+
dtype: float32
|
| 81 |
+
description: Fv molecular weight computed from sequence
|
| 82 |
+
- name: source_text
|
| 83 |
+
dtype: string
|
| 84 |
+
description: Verbatim label sentence(s) the row was parsed from
|
| 85 |
+
splits:
|
| 86 |
+
- name: full
|
| 87 |
+
num_examples: 165
|
| 88 |
+
license: cc-by-4.0
|
| 89 |
+
---
|
| 90 |
+
|
| 91 |
+
# BioFormBench: Two Open Benchmarks for Biologics Formulation Research
|
| 92 |
+
|
| 93 |
+
This release contains **two** datasets, kept separate because they answer different
|
| 94 |
+
questions and neither should be read as a substitute for the other.
|
| 95 |
+
|
| 96 |
+
## Data integrity note (please read before using either dataset)
|
| 97 |
+
|
| 98 |
+
An earlier internal draft of BioFormBench-Real contained 67 rows. Auditing
|
| 99 |
+
`source_title`/`source_id` provenance found that **18 of those rows had no
|
| 100 |
+
citation** and used placeholder identifiers (`protein_1`–`protein_5`) with
|
| 101 |
+
round, unverified descriptors (50.0 kDa / pI 7.2 / Tm 65.0 C) repeated across
|
| 102 |
+
otherwise-different molecules. Those rows have been **removed**. The 49 rows in
|
| 103 |
+
this release all trace to a PubMed Central ID and were checked against their
|
| 104 |
+
source text. If you have a copy of the 67-row file, discard it and use this one.
|
| 105 |
+
|
| 106 |
+
## 1. BioFormBench-Real (49 rows, 13 proteins)
|
| 107 |
+
|
| 108 |
+
Literature-mined formulation-outcome measurements (DSF Tm-shift, SEC %
|
| 109 |
+
aggregation, turbidity) for 13 real proteins across 11 primary papers, each row
|
| 110 |
+
traceable to its source. This is the dataset to use for any claim about
|
| 111 |
+
*stability-optimal* formulation, but at n=13 proteins (9 with enough
|
| 112 |
+
per-protein data for leave-one-protein-out evaluation) it is underpowered for a
|
| 113 |
+
definitive protein-conditionality verdict — see the companion paper's
|
| 114 |
+
Discussion for what scaling this further would require.
|
| 115 |
+
|
| 116 |
+
## 2. BioFormBench-Marketed (165 rows, 80 antibodies) — new in this release
|
| 117 |
+
|
| 118 |
+
165 formulation presentations for 80 FDA-approved antibody therapeutics,
|
| 119 |
+
deterministically parsed from FDA Structured Product Labeling (DailyMed) and
|
| 120 |
+
linked to real VH/VL variable-domain sequences from Thera-SAbDab. Every parsed
|
| 121 |
+
field keeps its verbatim source sentence (`source_text`) for audit. To our
|
| 122 |
+
knowledge this is the first open dataset connecting therapeutic antibody
|
| 123 |
+
sequence to marketed formulation composition at this scale.
|
| 124 |
+
|
| 125 |
+
This dataset encodes **what was chosen** for an approved product, not what is
|
| 126 |
+
necessarily stability-optimal — marketed choices are also shaped by
|
| 127 |
+
manufacturability, prior platform investment and regulatory precedent. Used at
|
| 128 |
+
full sample size (n=80) with proper multiple-comparison correction and
|
| 129 |
+
leave-one-protein-out validation, protein sequence identity does **not**
|
| 130 |
+
detectably predict the chosen pH or buffer beyond a constant "platform"
|
| 131 |
+
baseline (all sign-flip p > 0.8) — see the companion paper for the full
|
| 132 |
+
statistical analysis, including a worked example of how a naive n=27
|
| 133 |
+
subsample of this same data produces a spurious, non-reproducible positive
|
| 134 |
+
result (Spearman rho=-0.464, p=0.015, uncorrected) that a full-sample,
|
| 135 |
+
corrected, out-of-sample analysis overturns.
|
| 136 |
+
|
| 137 |
+
## Use cases
|
| 138 |
+
|
| 139 |
+
1. Test protein-conditional formulation hypotheses at adequate statistical
|
| 140 |
+
power, with the selection-artifact and platform-baseline results in the
|
| 141 |
+
companion paper as a required comparison point, not merely a possible one.
|
| 142 |
+
2. Train/evaluate predictive or generative formulation models against a
|
| 143 |
+
documented platform baseline rather than only random/uniform baselines.
|
| 144 |
+
3. Audit other mechanistic formulation simulators using the diagnostic
|
| 145 |
+
described in the companion paper (dead-slot spread, interior-argmax
|
| 146 |
+
fraction) against these real formulations.
|
| 147 |
+
4. Sequence-to-formulation representation learning (BioFormBench-Marketed
|
| 148 |
+
includes Fv-derived descriptors so no additional sequence processing is
|
| 149 |
+
required to get started).
|
| 150 |
+
|
| 151 |
+
## Files
|
| 152 |
+
|
| 153 |
+
- `bioformbench_real.csv` — 49 rows, BioFormBench-Real (see schema above).
|
| 154 |
+
- `bioformbench_marketed.csv` — 165 rows, BioFormBench-Marketed (see schema
|
| 155 |
+
above; full computed-descriptor and label-parse columns included).
|
| 156 |
+
|
| 157 |
+
## Known limitations
|
| 158 |
+
|
| 159 |
+
- BioFormBench-Real: n=13 proteins (9 LOPO-eligible) is small; treat any
|
| 160 |
+
per-protein result as illustrative, and prefer the aggregate statistics with
|
| 161 |
+
their reported confidence intervals.
|
| 162 |
+
- BioFormBench-Marketed: pH is extracted with a confidence flag
|
| 163 |
+
(`ph_is_range`/composition-sentence provenance in the full release columns);
|
| 164 |
+
the low-confidence stratum is retained rather than silently dropped, and the
|
| 165 |
+
companion paper shows the main finding (no sequence effect) holds in the
|
| 166 |
+
high-confidence stratum alone. Only 27–28 of 80 molecules have a fully
|
| 167 |
+
resolved buffer species *and* concentration; buffer-level analyses should
|
| 168 |
+
use that subset and are correspondingly lower-powered.
|
| 169 |
+
- Neither dataset should be used to generate or select actual formulations for
|
| 170 |
+
laboratory or clinical use without independent verification; see the
|
| 171 |
+
companion paper's Ethics statement.
|
| 172 |
+
|
| 173 |
+
## Citation
|
| 174 |
+
|
| 175 |
+
```bibtex
|
| 176 |
+
@dataset{kumar2026bioformbench,
|
| 177 |
+
title={BioFormBench: Two Open Benchmarks for Biologics Formulation Research},
|
| 178 |
+
author={Kumar, Bonthada Sravan},
|
| 179 |
+
year={2026},
|
| 180 |
+
publisher={Hugging Face Datasets},
|
| 181 |
+
url={https://huggingface.co/datasets/Sravankumarbonthada/BioFormBench}
|
| 182 |
+
}
|
| 183 |
+
```
|
| 184 |
+
|
| 185 |
+
## Sources
|
| 186 |
+
|
| 187 |
+
BioFormBench-Marketed is built from public FDA Structured Product Labeling
|
| 188 |
+
(DailyMed) and Thera-SAbDab (Raybould et al., Nucleic Acids Research 2020).
|
| 189 |
+
BioFormBench-Real is mined from 11 open-access PubMed Central articles, each
|
| 190 |
+
cited per-row via `source_id`.
|
| 191 |
+
|
| 192 |
+
## Contact
|
| 193 |
+
|
| 194 |
+
Bonthada Sravan Kumar — sravansaijohn@gmail.com — issues via GitHub
|
| 195 |
+
(Maheshbonthada/bioform-lm)
|
| 196 |
+
|
| 197 |
+
## License
|
| 198 |
+
|
| 199 |
+
CC-BY-4.0
|
| 200 |
+
|
| 201 |
+
---
|
| 202 |
+
|
| 203 |
+
**Last updated:** September 8, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bioformbench_extracted_real_20260903.csv
DELETED
|
@@ -1,9 +0,0 @@
|
|
| 1 |
-
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c,source_paper,source_doi_pmcid
|
| 2 |
-
PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.50,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 3 |
-
PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.70,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 4 |
-
Adalimumab_commercial,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 5 |
-
Adalimumab_concentrated_mannitol,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 6 |
-
Adalimumab_concentrated_mannitol_RT,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 7 |
-
X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756
|
| 8 |
-
mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,"{}",25.0,0.85,15.0,-1.0,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
| 9 |
-
mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,"{}",25.0,0.92,8.0,1.5,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bioformbench_extracted_real_batch2_20260903.csv
DELETED
|
@@ -1,17 +0,0 @@
|
|
| 1 |
-
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c,source_paper,source_doi_pmcid
|
| 2 |
-
Trastuzumab_histidine_reference,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,"{}",25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 3 |
-
Trastuzumab_arginine,150.0,7.2,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,1.00,0.0,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 4 |
-
Trastuzumab_glutamate,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,"{""sodium_glutamate"": 150.0}",25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 5 |
-
Omalizumab_histidine_reference,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,"{}",25.0,0.989,1.1,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 6 |
-
Omalizumab_arginine,150.0,7.2,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,0.997,0.3,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 7 |
-
bispecific_A_histidine_no_salt,110.0,6.9,58.0,histidine,50.0,5.5,0.0,150.0,"{}",25.0,0.96,4.0,-2.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 8 |
-
bispecific_A_histidine_150mM_NaCl,110.0,6.9,58.0,histidine,50.0,5.5,150.0,300.0,"{""nacl"": 150.0}",25.0,0.94,6.0,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 9 |
-
bispecific_A_histidine_500mM_NaCl,110.0,6.9,58.0,histidine,50.0,5.5,500.0,900.0,"{""nacl"": 500.0}",25.0,0.937,6.3,-1.2,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 10 |
-
bispecific_A_histidine_Arg,110.0,6.9,58.0,histidine,50.0,5.5,150.0,300.0,"{""arginine_hcl"": 150.0}",25.0,0.941,5.9,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 11 |
-
bispecific_A_acetate,110.0,6.9,58.0,acetate,50.0,5.5,50.0,180.0,"{}",25.0,0.944,5.6,-1.5,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 12 |
-
bispecific_A_citrate,110.0,6.9,58.0,citrate,50.0,5.5,50.0,180.0,"{}",25.0,0.961,3.9,-1.8,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 13 |
-
bispecific_A_phosphate,110.0,6.9,58.0,phosphate,50.0,5.5,50.0,180.0,"{}",25.0,0.948,5.2,-1.4,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 14 |
-
bispecific_A_histidine_40C,110.0,6.9,58.0,histidine,50.0,5.5,0.0,150.0,"{}",40.0,0.95,5.0,-1.5,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 15 |
-
mAb_aggregation_prone_1,150.0,7.1,60.0,histidine,20.0,6.0,140.0,280.0,"{}",45.0,0.85,15.0,-0.5,Machine learning prediction of antibody aggregation and viscosity,PMC8794240
|
| 16 |
-
mAb_stable_reference,150.0,7.1,55.0,histidine,20.0,6.0,140.0,280.0,"{}",45.0,0.97,3.0,1.0,Machine learning prediction of antibody aggregation and viscosity,PMC8794240
|
| 17 |
-
mAb_high_viscosity_1,150.0,7.2,56.5,histidine,20.0,6.0,140.0,280.0,"{}",25.0,0.92,8.0,0.5,Machine learning prediction of antibody aggregation and viscosity,PMC8794240
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bioformbench_extracted_real_batch3_20260903.csv
DELETED
|
@@ -1,15 +0,0 @@
|
|
| 1 |
-
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c,source_paper,source_doi_pmcid
|
| 2 |
-
A33_Fab_citrate_no_glycine,27.0,6.8,77.1,citrate,20.0,4.5,50.0,150.0,"{}",25.0,0.90,10.0,0.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 3 |
-
A33_Fab_citrate_glycine10,27.0,6.8,79.1,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 10.0}",25.0,0.92,8.0,2.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 4 |
-
A33_Fab_citrate_glycine20,27.0,6.8,79.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 20.0}",25.0,0.93,7.0,2.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 5 |
-
A33_Fab_citrate_glycine30,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 30.0}",25.0,0.94,6.0,5.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 6 |
-
A33_Fab_citrate_glycine40,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 40.0}",25.0,0.95,5.0,5.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 7 |
-
A33_Fab_citrate_glycine50,27.0,6.8,83.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 50.0}",25.0,0.96,4.0,6.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 8 |
-
A33_Fab_citrate_glycine60,27.0,6.8,83.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 60.0}",25.0,0.97,3.0,6.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 9 |
-
A33_Fab_phosphate_glycine20,27.0,6.8,78.0,phosphate,10.0,7.0,50.0,150.0,"{""glycine"": 20.0}",25.0,0.94,6.0,1.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 10 |
-
Fab_citrate_dilute,27.5,6.9,70.8,citrate,20.0,4.0,200.0,400.0,"{}",25.0,0.88,12.0,0.0,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 11 |
-
Fab_citrate_medium,27.5,6.9,77.2,citrate,20.0,4.0,200.0,400.0,"{}",25.0,0.93,7.0,6.4,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 12 |
-
Fab_citrate_concentrated,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,"{}",25.0,0.95,5.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 13 |
-
Fab_citrate_high_conc_tween80,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,"{""tween80"": 0.01}",25.0,0.96,4.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 14 |
-
Biosimilar_mAb_phosphate_cold,150.0,7.3,72.0,phosphate,20.0,7.4,188.0,380.0,"{}",5.0,0.98,2.0,0.0,Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques,PMC9986942
|
| 15 |
-
Biosimilar_mAb_phosphate_RT,150.0,7.3,72.0,phosphate,20.0,7.4,188.0,380.0,"{}",25.0,0.96,4.0,-2.0,Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques,PMC9986942
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bioformbench_extracted_real_batch4_20260903.csv
DELETED
|
@@ -1,4 +0,0 @@
|
|
| 1 |
-
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c,source_paper,source_doi_pmcid
|
| 2 |
-
rhIL1ra_MES_60mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,60.0,140.0,"{""NaCl"": 60.0}",25.0,0.85,15.0,0.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
| 3 |
-
rhIL1ra_MES_150mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,150.0,300.0,"{""NaCl"": 150.0}",25.0,0.90,10.0,1.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
| 4 |
-
rhIL1ra_MES_500mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,500.0,950.0,"{""NaCl"": 500.0}",25.0,0.94,6.0,2.5,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bioformbench_marketed.csv
ADDED
|
The diff for this file is too large to render.
See raw diff
|
|
|
bioformbench_seed.csv → bioformbench_real.csv
RENAMED
|
@@ -1,55 +1,37 @@
|
|
| 1 |
-
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c
|
| 2 |
-
|
| 3 |
-
|
| 4 |
-
protein_1,50.0,7.2,65.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.65,5.8,4.0
|
| 5 |
-
protein_1,50.0,7.2,65.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0, ""tween80"": 0.01}",25.0,0.88,1.8,10.0
|
| 6 |
-
protein_2,75.0,6.8,58.0,histidine,50.0,6.5,150.0,300.0,"{""sucrose"": 100.0}",25.0,0.80,3.5,6.0
|
| 7 |
-
protein_2,75.0,6.8,58.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.89,1.5,11.0
|
| 8 |
-
protein_2,75.0,6.8,58.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.72,4.2,5.0
|
| 9 |
-
protein_2,75.0,6.8,58.0,histidine,50.0,6.5,150.0,300.0,"{""sucrose"": 100.0, ""polysorbate20"": 0.01}",25.0,0.83,2.8,7.5
|
| 10 |
-
protein_3,45.0,8.1,62.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0}",25.0,0.82,3.2,7.5
|
| 11 |
-
protein_3,45.0,8.1,62.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 250.0}",25.0,0.90,1.0,13.0
|
| 12 |
-
protein_3,45.0,8.1,62.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.68,5.5,3.5
|
| 13 |
-
protein_3,45.0,8.1,62.0,citrate,60.0,5.0,120.0,280.0,"{""glycerol"": 10.0}",25.0,0.75,4.0,6.0
|
| 14 |
-
protein_4,120.0,5.9,70.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0}",25.0,0.84,2.8,8.5
|
| 15 |
-
protein_4,120.0,5.9,70.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.91,0.9,12.5
|
| 16 |
-
protein_4,120.0,5.9,70.0,acetate,75.0,5.5,100.0,250.0,"{""mannitol"": 150.0}",25.0,0.70,4.5,4.5
|
| 17 |
-
protein_5,60.0,7.5,64.0,histidine,50.0,6.5,150.0,300.0,"{""sucrose"": 100.0}",25.0,0.81,3.5,7.0
|
| 18 |
-
protein_5,60.0,7.5,64.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.88,1.3,11.0
|
| 19 |
-
protein_5,60.0,7.5,64.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.69,4.8,4.8
|
| 20 |
-
PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.50,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 21 |
-
PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.70,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 22 |
Adalimumab_commercial,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 23 |
Adalimumab_concentrated_mannitol,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 24 |
Adalimumab_concentrated_mannitol_RT,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 25 |
X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756
|
| 26 |
-
mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,
|
| 27 |
-
mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,
|
| 28 |
-
PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.
|
| 29 |
-
PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.
|
| 30 |
Adalimumab_commercial,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 31 |
Adalimumab_concentrated_mannitol,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 32 |
Adalimumab_concentrated_mannitol_RT,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 33 |
X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756
|
| 34 |
-
mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,
|
| 35 |
-
mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,
|
| 36 |
-
Trastuzumab_histidine_reference,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,
|
| 37 |
-
Trastuzumab_arginine,150.0,7.2,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,1.
|
| 38 |
Trastuzumab_glutamate,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,"{""sodium_glutamate"": 150.0}",25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 39 |
-
Omalizumab_histidine_reference,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,
|
| 40 |
Omalizumab_arginine,150.0,7.2,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,0.997,0.3,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 41 |
-
bispecific_A_histidine_no_salt,110.0,6.9,58.0,histidine,50.0,5.5,0.0,150.0,
|
| 42 |
bispecific_A_histidine_150mM_NaCl,110.0,6.9,58.0,histidine,50.0,5.5,150.0,300.0,"{""nacl"": 150.0}",25.0,0.94,6.0,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 43 |
bispecific_A_histidine_500mM_NaCl,110.0,6.9,58.0,histidine,50.0,5.5,500.0,900.0,"{""nacl"": 500.0}",25.0,0.937,6.3,-1.2,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 44 |
bispecific_A_histidine_Arg,110.0,6.9,58.0,histidine,50.0,5.5,150.0,300.0,"{""arginine_hcl"": 150.0}",25.0,0.941,5.9,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 45 |
-
bispecific_A_acetate,110.0,6.9,58.0,acetate,50.0,5.5,50.0,180.0,
|
| 46 |
-
bispecific_A_citrate,110.0,6.9,58.0,citrate,50.0,5.5,50.0,180.0,
|
| 47 |
-
bispecific_A_phosphate,110.0,6.9,58.0,phosphate,50.0,5.5,50.0,180.0,
|
| 48 |
-
bispecific_A_histidine_40C,110.0,6.9,58.0,histidine,50.0,5.5,0.0,150.0,
|
| 49 |
-
mAb_aggregation_prone_1,150.0,7.1,60.0,histidine,20.0,6.0,140.0,280.0,
|
| 50 |
-
mAb_stable_reference,150.0,7.1,55.0,histidine,20.0,6.0,140.0,280.0,
|
| 51 |
-
mAb_high_viscosity_1,150.0,7.2,56.5,histidine,20.0,6.0,140.0,280.0,
|
| 52 |
-
A33_Fab_citrate_no_glycine,27.0,6.8,77.1,citrate,20.0,4.5,50.0,150.0,
|
| 53 |
A33_Fab_citrate_glycine10,27.0,6.8,79.1,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 10.0}",25.0,0.92,8.0,2.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 54 |
A33_Fab_citrate_glycine20,27.0,6.8,79.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 20.0}",25.0,0.93,7.0,2.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 55 |
A33_Fab_citrate_glycine30,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 30.0}",25.0,0.94,6.0,5.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
|
@@ -57,12 +39,12 @@ A33_Fab_citrate_glycine40,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"
|
|
| 57 |
A33_Fab_citrate_glycine50,27.0,6.8,83.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 50.0}",25.0,0.96,4.0,6.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 58 |
A33_Fab_citrate_glycine60,27.0,6.8,83.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 60.0}",25.0,0.97,3.0,6.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 59 |
A33_Fab_phosphate_glycine20,27.0,6.8,78.0,phosphate,10.0,7.0,50.0,150.0,"{""glycine"": 20.0}",25.0,0.94,6.0,1.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 60 |
-
Fab_citrate_dilute,27.5,6.9,70.8,citrate,20.0,4.0,200.0,400.0,
|
| 61 |
-
Fab_citrate_medium,27.5,6.9,77.2,citrate,20.0,4.0,200.0,400.0,
|
| 62 |
-
Fab_citrate_concentrated,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,
|
| 63 |
Fab_citrate_high_conc_tween80,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,"{""tween80"": 0.01}",25.0,0.96,4.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 64 |
-
Biosimilar_mAb_phosphate_cold,150.0,7.3,72.0,phosphate,20.0,7.4,188.0,380.0,
|
| 65 |
-
Biosimilar_mAb_phosphate_RT,150.0,7.3,72.0,phosphate,20.0,7.4,188.0,380.0,
|
| 66 |
rhIL1ra_MES_60mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,60.0,140.0,"{""NaCl"": 60.0}",25.0,0.85,15.0,0.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
| 67 |
-
rhIL1ra_MES_150mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,150.0,300.0,"{""NaCl"": 150.0}",25.0,0.
|
| 68 |
rhIL1ra_MES_500mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,500.0,950.0,"{""NaCl"": 500.0}",25.0,0.94,6.0,2.5,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
|
|
|
| 1 |
+
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c,source_title,source_id
|
| 2 |
+
PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.5,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 3 |
+
PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.7,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4 |
Adalimumab_commercial,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 5 |
Adalimumab_concentrated_mannitol,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 6 |
Adalimumab_concentrated_mannitol_RT,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 7 |
X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756
|
| 8 |
+
mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,{},25.0,0.85,15.0,-1.0,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
| 9 |
+
mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,{},25.0,0.92,8.0,1.5,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
| 10 |
+
PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.5,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 11 |
+
PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.7,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 12 |
Adalimumab_commercial,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 13 |
Adalimumab_concentrated_mannitol,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 14 |
Adalimumab_concentrated_mannitol_RT,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 15 |
X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756
|
| 16 |
+
mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,{},25.0,0.85,15.0,-1.0,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
| 17 |
+
mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,{},25.0,0.92,8.0,1.5,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
| 18 |
+
Trastuzumab_histidine_reference,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,{},25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 19 |
+
Trastuzumab_arginine,150.0,7.2,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,1.0,0.0,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 20 |
Trastuzumab_glutamate,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,"{""sodium_glutamate"": 150.0}",25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 21 |
+
Omalizumab_histidine_reference,150.0,7.2,71.6,histidine,10.0,6.5,150.0,310.0,{},25.0,0.989,1.1,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 22 |
Omalizumab_arginine,150.0,7.2,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,0.997,0.3,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152
|
| 23 |
+
bispecific_A_histidine_no_salt,110.0,6.9,58.0,histidine,50.0,5.5,0.0,150.0,{},25.0,0.96,4.0,-2.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 24 |
bispecific_A_histidine_150mM_NaCl,110.0,6.9,58.0,histidine,50.0,5.5,150.0,300.0,"{""nacl"": 150.0}",25.0,0.94,6.0,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 25 |
bispecific_A_histidine_500mM_NaCl,110.0,6.9,58.0,histidine,50.0,5.5,500.0,900.0,"{""nacl"": 500.0}",25.0,0.937,6.3,-1.2,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 26 |
bispecific_A_histidine_Arg,110.0,6.9,58.0,histidine,50.0,5.5,150.0,300.0,"{""arginine_hcl"": 150.0}",25.0,0.941,5.9,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 27 |
+
bispecific_A_acetate,110.0,6.9,58.0,acetate,50.0,5.5,50.0,180.0,{},25.0,0.944,5.6,-1.5,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 28 |
+
bispecific_A_citrate,110.0,6.9,58.0,citrate,50.0,5.5,50.0,180.0,{},25.0,0.961,3.9,-1.8,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 29 |
+
bispecific_A_phosphate,110.0,6.9,58.0,phosphate,50.0,5.5,50.0,180.0,{},25.0,0.948,5.2,-1.4,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 30 |
+
bispecific_A_histidine_40C,110.0,6.9,58.0,histidine,50.0,5.5,0.0,150.0,{},40.0,0.95,5.0,-1.5,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937
|
| 31 |
+
mAb_aggregation_prone_1,150.0,7.1,60.0,histidine,20.0,6.0,140.0,280.0,{},45.0,0.85,15.0,-0.5,Machine learning prediction of antibody aggregation and viscosity,PMC8794240
|
| 32 |
+
mAb_stable_reference,150.0,7.1,55.0,histidine,20.0,6.0,140.0,280.0,{},45.0,0.97,3.0,1.0,Machine learning prediction of antibody aggregation and viscosity,PMC8794240
|
| 33 |
+
mAb_high_viscosity_1,150.0,7.2,56.5,histidine,20.0,6.0,140.0,280.0,{},25.0,0.92,8.0,0.5,Machine learning prediction of antibody aggregation and viscosity,PMC8794240
|
| 34 |
+
A33_Fab_citrate_no_glycine,27.0,6.8,77.1,citrate,20.0,4.5,50.0,150.0,{},25.0,0.9,10.0,0.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 35 |
A33_Fab_citrate_glycine10,27.0,6.8,79.1,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 10.0}",25.0,0.92,8.0,2.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 36 |
A33_Fab_citrate_glycine20,27.0,6.8,79.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 20.0}",25.0,0.93,7.0,2.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 37 |
A33_Fab_citrate_glycine30,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 30.0}",25.0,0.94,6.0,5.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
|
|
|
| 39 |
A33_Fab_citrate_glycine50,27.0,6.8,83.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 50.0}",25.0,0.96,4.0,6.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 40 |
A33_Fab_citrate_glycine60,27.0,6.8,83.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 60.0}",25.0,0.97,3.0,6.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 41 |
A33_Fab_phosphate_glycine20,27.0,6.8,78.0,phosphate,10.0,7.0,50.0,150.0,"{""glycine"": 20.0}",25.0,0.94,6.0,1.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065
|
| 42 |
+
Fab_citrate_dilute,27.5,6.9,70.8,citrate,20.0,4.0,200.0,400.0,{},25.0,0.88,12.0,0.0,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 43 |
+
Fab_citrate_medium,27.5,6.9,77.2,citrate,20.0,4.0,200.0,400.0,{},25.0,0.93,7.0,6.4,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 44 |
+
Fab_citrate_concentrated,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,{},25.0,0.95,5.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 45 |
Fab_citrate_high_conc_tween80,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,"{""tween80"": 0.01}",25.0,0.96,4.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210
|
| 46 |
+
Biosimilar_mAb_phosphate_cold,150.0,7.3,72.0,phosphate,20.0,7.4,188.0,380.0,{},5.0,0.98,2.0,0.0,Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques,PMC9986942
|
| 47 |
+
Biosimilar_mAb_phosphate_RT,150.0,7.3,72.0,phosphate,20.0,7.4,188.0,380.0,{},25.0,0.96,4.0,-2.0,Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques,PMC9986942
|
| 48 |
rhIL1ra_MES_60mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,60.0,140.0,"{""NaCl"": 60.0}",25.0,0.85,15.0,0.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
| 49 |
+
rhIL1ra_MES_150mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,150.0,300.0,"{""NaCl"": 150.0}",25.0,0.9,10.0,1.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
| 50 |
rhIL1ra_MES_500mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,500.0,950.0,"{""NaCl"": 500.0}",25.0,0.94,6.0,2.5,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359
|
bioformbench_seed_backup_20260903.csv
DELETED
|
@@ -1,27 +0,0 @@
|
|
| 1 |
-
protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c
|
| 2 |
-
protein_1,50.0,7.2,65.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0}",25.0,0.85,2.5,8.0
|
| 3 |
-
protein_1,50.0,7.2,65.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.92,1.2,12.0
|
| 4 |
-
protein_1,50.0,7.2,65.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.65,5.8,4.0
|
| 5 |
-
protein_1,50.0,7.2,65.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0, ""tween80"": 0.01}",25.0,0.88,1.8,10.0
|
| 6 |
-
protein_2,75.0,6.8,58.0,histidine,50.0,6.5,150.0,300.0,"{""sucrose"": 100.0}",25.0,0.80,3.5,6.0
|
| 7 |
-
protein_2,75.0,6.8,58.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.89,1.5,11.0
|
| 8 |
-
protein_2,75.0,6.8,58.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.72,4.2,5.0
|
| 9 |
-
protein_2,75.0,6.8,58.0,histidine,50.0,6.5,150.0,300.0,"{""sucrose"": 100.0, ""polysorbate20"": 0.01}",25.0,0.83,2.8,7.5
|
| 10 |
-
protein_3,45.0,8.1,62.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0}",25.0,0.82,3.2,7.5
|
| 11 |
-
protein_3,45.0,8.1,62.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 250.0}",25.0,0.90,1.0,13.0
|
| 12 |
-
protein_3,45.0,8.1,62.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.68,5.5,3.5
|
| 13 |
-
protein_3,45.0,8.1,62.0,citrate,60.0,5.0,120.0,280.0,"{""glycerol"": 10.0}",25.0,0.75,4.0,6.0
|
| 14 |
-
protein_4,120.0,5.9,70.0,histidine,50.0,6.5,150.0,300.0,"{""trehalose"": 100.0}",25.0,0.84,2.8,8.5
|
| 15 |
-
protein_4,120.0,5.9,70.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.91,0.9,12.5
|
| 16 |
-
protein_4,120.0,5.9,70.0,acetate,75.0,5.5,100.0,250.0,"{""mannitol"": 150.0}",25.0,0.70,4.5,4.5
|
| 17 |
-
protein_5,60.0,7.5,64.0,histidine,50.0,6.5,150.0,300.0,"{""sucrose"": 100.0}",25.0,0.81,3.5,7.0
|
| 18 |
-
protein_5,60.0,7.5,64.0,phosphate,100.0,7.0,200.0,350.0,"{""trehalose"": 200.0}",25.0,0.88,1.3,11.0
|
| 19 |
-
protein_5,60.0,7.5,64.0,acetate,75.0,5.5,100.0,250.0,"{""sorbitol"": 150.0}",25.0,0.69,4.8,4.8
|
| 20 |
-
PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.50,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 21 |
-
PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.70,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243
|
| 22 |
-
Adalimumab_commercial,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 23 |
-
Adalimumab_concentrated_mannitol,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 24 |
-
Adalimumab_concentrated_mannitol_RT,148.0,7.2,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033
|
| 25 |
-
X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756
|
| 26 |
-
mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,"{}",25.0,0.85,15.0,-1.0,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
| 27 |
-
mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,"{}",25.0,0.92,8.0,1.5,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
synthetic_generator.py
DELETED
|
@@ -1,363 +0,0 @@
|
|
| 1 |
-
"""
|
| 2 |
-
Synthetic Formulation Data Generator
|
| 3 |
-
|
| 4 |
-
Generates high-quality synthetic (protein, formulation) → (stability_outcome) triples
|
| 5 |
-
using the validated mechanistic simulator. This synthetic corpus is used for
|
| 6 |
-
pretraining the transformer model.
|
| 7 |
-
|
| 8 |
-
Production features:
|
| 9 |
-
- Stratified sampling (covers diverse protein/formulation space)
|
| 10 |
-
- Quality filtering (removes unphysical samples)
|
| 11 |
-
- Reproducible with seed control
|
| 12 |
-
- Efficient batch generation
|
| 13 |
-
- Parallel generation capability
|
| 14 |
-
"""
|
| 15 |
-
|
| 16 |
-
import numpy as np
|
| 17 |
-
import pandas as pd
|
| 18 |
-
from typing import List, Dict, Tuple, Optional
|
| 19 |
-
from pathlib import Path
|
| 20 |
-
import logging
|
| 21 |
-
from dataclasses import dataclass
|
| 22 |
-
import json
|
| 23 |
-
from tqdm import tqdm
|
| 24 |
-
import sys
|
| 25 |
-
|
| 26 |
-
sys.path.insert(0, str(Path(__file__).parent.parent))
|
| 27 |
-
|
| 28 |
-
from simulator.mechanistic_sim import (
|
| 29 |
-
BiologicsFormulationSimulator,
|
| 30 |
-
ProteinDescriptor,
|
| 31 |
-
FormulationComposition,
|
| 32 |
-
SimulationOutput,
|
| 33 |
-
)
|
| 34 |
-
from config import CFG, SyntheticDataConfig
|
| 35 |
-
|
| 36 |
-
logger = logging.getLogger(__name__)
|
| 37 |
-
|
| 38 |
-
|
| 39 |
-
@dataclass
|
| 40 |
-
class SyntheticSample:
|
| 41 |
-
"""Single synthetic training sample."""
|
| 42 |
-
protein_mw_kda: float
|
| 43 |
-
protein_pi: float
|
| 44 |
-
protein_hydrophobicity: float
|
| 45 |
-
protein_tm_baseline_c: float
|
| 46 |
-
buffer_species: str
|
| 47 |
-
buffer_conc_mm: float
|
| 48 |
-
ph: float
|
| 49 |
-
ionic_strength_mm: float
|
| 50 |
-
osmolarity_mosm_kg: float
|
| 51 |
-
stabilizers_json: str # JSON string of stabilizer dict
|
| 52 |
-
temperature_c: float
|
| 53 |
-
storage_duration_days: float
|
| 54 |
-
# Outcomes
|
| 55 |
-
tm_shift_c: float
|
| 56 |
-
predicted_tm_c: float
|
| 57 |
-
aggregation_risk_combined: float
|
| 58 |
-
predicted_aggregation_percent: float
|
| 59 |
-
stability_score: float
|
| 60 |
-
|
| 61 |
-
def to_dict(self) -> Dict:
|
| 62 |
-
"""Convert to dict for DataFrame."""
|
| 63 |
-
return {
|
| 64 |
-
'protein_mw_kda': self.protein_mw_kda,
|
| 65 |
-
'protein_pi': self.protein_pi,
|
| 66 |
-
'protein_hydrophobicity': self.protein_hydrophobicity,
|
| 67 |
-
'protein_tm_baseline_c': self.protein_tm_baseline_c,
|
| 68 |
-
'buffer_species': self.buffer_species,
|
| 69 |
-
'buffer_conc_mm': self.buffer_conc_mm,
|
| 70 |
-
'ph': self.ph,
|
| 71 |
-
'ionic_strength_mm': self.ionic_strength_mm,
|
| 72 |
-
'osmolarity_mosm_kg': self.osmolarity_mosm_kg,
|
| 73 |
-
'stabilizers_json': self.stabilizers_json,
|
| 74 |
-
'temperature_c': self.temperature_c,
|
| 75 |
-
'storage_duration_days': self.storage_duration_days,
|
| 76 |
-
'tm_shift_c': self.tm_shift_c,
|
| 77 |
-
'predicted_tm_c': self.predicted_tm_c,
|
| 78 |
-
'aggregation_risk_combined': self.aggregation_risk_combined,
|
| 79 |
-
'predicted_aggregation_percent': self.predicted_aggregation_percent,
|
| 80 |
-
'stability_score': self.stability_score,
|
| 81 |
-
}
|
| 82 |
-
|
| 83 |
-
|
| 84 |
-
class SyntheticDataGenerator:
|
| 85 |
-
"""Generates high-quality synthetic training data."""
|
| 86 |
-
|
| 87 |
-
def __init__(
|
| 88 |
-
self,
|
| 89 |
-
num_samples: int = 500_000,
|
| 90 |
-
seed: int = 42,
|
| 91 |
-
config: Optional[SyntheticDataConfig] = None,
|
| 92 |
-
):
|
| 93 |
-
"""
|
| 94 |
-
Initialize synthetic data generator.
|
| 95 |
-
|
| 96 |
-
Args:
|
| 97 |
-
num_samples: Number of synthetic samples to generate
|
| 98 |
-
seed: Random seed for reproducibility
|
| 99 |
-
config: SyntheticDataConfig from config.py
|
| 100 |
-
"""
|
| 101 |
-
self.num_samples = num_samples
|
| 102 |
-
self.seed = seed
|
| 103 |
-
self.rng = np.random.RandomState(seed)
|
| 104 |
-
self.config = config or CFG.synthetic_data
|
| 105 |
-
|
| 106 |
-
# Initialize simulator
|
| 107 |
-
self.simulator = BiologicsFormulationSimulator(
|
| 108 |
-
config_dict={
|
| 109 |
-
'hamaker_constant': CFG.simulator.hamaker_constant,
|
| 110 |
-
'bjerrum_length': CFG.simulator.bjerrum_length,
|
| 111 |
-
'ph_penalty_per_unit_sq': CFG.simulator.ph_penalty_per_unit_sq,
|
| 112 |
-
'osmol_positive_slope': CFG.simulator.osmol_positive_slope,
|
| 113 |
-
'osmol_negative_slope': CFG.simulator.osmol_negative_slope,
|
| 114 |
-
'aggregation_rate_constant': CFG.simulator.aggregation_rate_constant,
|
| 115 |
-
'stabilizer_effects': CFG.simulator.stabilizer_effects,
|
| 116 |
-
}
|
| 117 |
-
)
|
| 118 |
-
|
| 119 |
-
logger.info(f"SyntheticDataGenerator initialized: {num_samples} samples, seed={seed}")
|
| 120 |
-
|
| 121 |
-
def generate(self) -> pd.DataFrame:
|
| 122 |
-
"""
|
| 123 |
-
Generate synthetic dataset.
|
| 124 |
-
|
| 125 |
-
Returns:
|
| 126 |
-
DataFrame with synthetic (protein, formulation) → outcome triples
|
| 127 |
-
|
| 128 |
-
Process:
|
| 129 |
-
1. Sample random proteins from descriptor space
|
| 130 |
-
2. Sample random formulations from composition space
|
| 131 |
-
3. Run simulator for each pair
|
| 132 |
-
4. Filter out unphysical/invalid samples
|
| 133 |
-
5. Return as DataFrame
|
| 134 |
-
|
| 135 |
-
This is CPU-efficient and can generate millions of samples.
|
| 136 |
-
"""
|
| 137 |
-
samples = []
|
| 138 |
-
skipped = 0
|
| 139 |
-
|
| 140 |
-
logger.info(f"Generating {self.num_samples} synthetic samples...")
|
| 141 |
-
|
| 142 |
-
for i in tqdm(range(self.num_samples), desc="Generating synthetic data"):
|
| 143 |
-
try:
|
| 144 |
-
# Sample random protein
|
| 145 |
-
protein = self._sample_protein()
|
| 146 |
-
|
| 147 |
-
# Sample random formulation
|
| 148 |
-
formulation = self._sample_formulation()
|
| 149 |
-
|
| 150 |
-
# Run simulator
|
| 151 |
-
output = self.simulator.predict(protein, formulation)
|
| 152 |
-
|
| 153 |
-
# Create sample
|
| 154 |
-
stabilizers_dict = formulation.stabilizers or {}
|
| 155 |
-
sample = SyntheticSample(
|
| 156 |
-
protein_mw_kda=protein.mw_kda,
|
| 157 |
-
protein_pi=protein.pi,
|
| 158 |
-
protein_hydrophobicity=protein.hydrophobicity,
|
| 159 |
-
protein_tm_baseline_c=protein.tm_baseline_c,
|
| 160 |
-
buffer_species=formulation.buffer_species,
|
| 161 |
-
buffer_conc_mm=formulation.buffer_conc_mm,
|
| 162 |
-
ph=formulation.ph,
|
| 163 |
-
ionic_strength_mm=formulation.ionic_strength_mm,
|
| 164 |
-
osmolarity_mosm_kg=formulation.osmolarity_mosm_kg,
|
| 165 |
-
stabilizers_json=json.dumps(stabilizers_dict),
|
| 166 |
-
temperature_c=formulation.temperature_c,
|
| 167 |
-
storage_duration_days=formulation.storage_duration_days,
|
| 168 |
-
tm_shift_c=output.tm_shift_c,
|
| 169 |
-
predicted_tm_c=output.predicted_tm_c,
|
| 170 |
-
aggregation_risk_combined=output.aggregation_risk_combined,
|
| 171 |
-
predicted_aggregation_percent=output.predicted_aggregation_percent,
|
| 172 |
-
stability_score=output.stability_score,
|
| 173 |
-
)
|
| 174 |
-
|
| 175 |
-
# Quality check: ensure sample is physically plausible
|
| 176 |
-
if self._is_valid_sample(sample):
|
| 177 |
-
samples.append(sample.to_dict())
|
| 178 |
-
else:
|
| 179 |
-
skipped += 1
|
| 180 |
-
|
| 181 |
-
except Exception as e:
|
| 182 |
-
skipped += 1
|
| 183 |
-
if i % 10000 == 0:
|
| 184 |
-
logger.debug(f"Skipped sample {i}: {e}")
|
| 185 |
-
continue
|
| 186 |
-
|
| 187 |
-
logger.info(f"Generated {len(samples)} valid samples, skipped {skipped}")
|
| 188 |
-
|
| 189 |
-
# Convert to DataFrame
|
| 190 |
-
df = pd.DataFrame(samples)
|
| 191 |
-
return df
|
| 192 |
-
|
| 193 |
-
def _sample_protein(self) -> ProteinDescriptor:
|
| 194 |
-
"""Sample random protein descriptor."""
|
| 195 |
-
mw = self.rng.uniform(*self.config.protein_mw_range)
|
| 196 |
-
pi = self.rng.uniform(*self.config.protein_pi_range)
|
| 197 |
-
hydro = self.rng.uniform(*self.config.protein_hydrophobicity_range)
|
| 198 |
-
tm = self.rng.uniform(30, 85) # typical Tm range
|
| 199 |
-
|
| 200 |
-
return ProteinDescriptor(
|
| 201 |
-
mw_kda=mw,
|
| 202 |
-
pi=pi,
|
| 203 |
-
hydrophobicity=hydro,
|
| 204 |
-
tm_baseline_c=tm,
|
| 205 |
-
)
|
| 206 |
-
|
| 207 |
-
def _sample_formulation(self) -> FormulationComposition:
|
| 208 |
-
"""Sample random formulation composition."""
|
| 209 |
-
# Buffer
|
| 210 |
-
buffer_species = self.rng.choice(self.config.buffer_types)
|
| 211 |
-
buffer_conc = self.rng.uniform(*self.config.buffer_concentration_range)
|
| 212 |
-
|
| 213 |
-
# pH
|
| 214 |
-
ph = self.rng.uniform(*self.config.ph_range)
|
| 215 |
-
|
| 216 |
-
# Ionic strength
|
| 217 |
-
ionic_strength = self.rng.uniform(*self.config.ionic_strength_range)
|
| 218 |
-
|
| 219 |
-
# Osmolarity (derived from buffer + ions)
|
| 220 |
-
osmolarity = self.rng.uniform(*self.config.osmolarity_range)
|
| 221 |
-
|
| 222 |
-
# Stabilizers (multi-select)
|
| 223 |
-
stabilizers = {}
|
| 224 |
-
num_stab = self.rng.randint(0, self.config.num_stabilizers_per_sample + 1)
|
| 225 |
-
|
| 226 |
-
for _ in range(num_stab):
|
| 227 |
-
stab_name = self.rng.choice(list(self.config.stabilizer_pool.keys()))
|
| 228 |
-
min_conc, max_conc = self.config.stabilizer_pool[stab_name]
|
| 229 |
-
|
| 230 |
-
# Avoid adding zero-concentration stabilizers
|
| 231 |
-
if max_conc > 0:
|
| 232 |
-
conc = self.rng.uniform(min_conc + 0.01, max_conc)
|
| 233 |
-
stabilizers[stab_name] = conc
|
| 234 |
-
|
| 235 |
-
# Storage conditions
|
| 236 |
-
temperature = self.rng.uniform(*self.config.temperature_range)
|
| 237 |
-
duration = self.rng.uniform(*self.config.storage_duration_range)
|
| 238 |
-
|
| 239 |
-
return FormulationComposition(
|
| 240 |
-
buffer_species=buffer_species,
|
| 241 |
-
buffer_conc_mm=buffer_conc,
|
| 242 |
-
ph=ph,
|
| 243 |
-
ionic_strength_mm=ionic_strength,
|
| 244 |
-
osmolarity_mosm_kg=osmolarity,
|
| 245 |
-
stabilizers=stabilizers,
|
| 246 |
-
temperature_c=temperature,
|
| 247 |
-
storage_duration_days=duration,
|
| 248 |
-
)
|
| 249 |
-
|
| 250 |
-
def _is_valid_sample(self, sample: SyntheticSample) -> bool:
|
| 251 |
-
"""
|
| 252 |
-
Quality filter: reject unphysical or invalid samples.
|
| 253 |
-
|
| 254 |
-
Checks:
|
| 255 |
-
- Aggregation % in reasonable range
|
| 256 |
-
- Stability score is valid
|
| 257 |
-
- Outcomes are finite (not NaN/inf)
|
| 258 |
-
"""
|
| 259 |
-
# Check for NaN/inf
|
| 260 |
-
if not np.isfinite(sample.aggregation_risk_combined):
|
| 261 |
-
return False
|
| 262 |
-
if not np.isfinite(sample.stability_score):
|
| 263 |
-
return False
|
| 264 |
-
|
| 265 |
-
# Aggregation should be 0-100%
|
| 266 |
-
if not (0 <= sample.predicted_aggregation_percent <= 100):
|
| 267 |
-
return False
|
| 268 |
-
|
| 269 |
-
# Stability score should be 0-1
|
| 270 |
-
if not (0 <= sample.stability_score <= 1):
|
| 271 |
-
return False
|
| 272 |
-
|
| 273 |
-
# At least some buffer
|
| 274 |
-
if sample.buffer_conc_mm < 1:
|
| 275 |
-
return False
|
| 276 |
-
|
| 277 |
-
return True
|
| 278 |
-
|
| 279 |
-
def save(self, path: Path) -> None:
|
| 280 |
-
"""Generate and save synthetic data to CSV/Parquet."""
|
| 281 |
-
df = self.generate()
|
| 282 |
-
|
| 283 |
-
# Save as both CSV (human-readable) and Parquet (efficient)
|
| 284 |
-
csv_path = path.with_suffix('.csv')
|
| 285 |
-
parquet_path = path.with_suffix('.parquet')
|
| 286 |
-
|
| 287 |
-
logger.info(f"Saving {len(df)} samples to {csv_path}")
|
| 288 |
-
df.to_csv(csv_path, index=False)
|
| 289 |
-
|
| 290 |
-
logger.info(f"Saving to Parquet: {parquet_path}")
|
| 291 |
-
df.to_parquet(parquet_path, index=False)
|
| 292 |
-
|
| 293 |
-
# Summary statistics
|
| 294 |
-
logger.info("\n" + "=" * 70)
|
| 295 |
-
logger.info("SYNTHETIC DATA SUMMARY")
|
| 296 |
-
logger.info("=" * 70)
|
| 297 |
-
logger.info(f"Total samples: {len(df)}")
|
| 298 |
-
logger.info(f"\nProtein descriptors:")
|
| 299 |
-
logger.info(df[['protein_mw_kda', 'protein_pi', 'protein_tm_baseline_c']].describe())
|
| 300 |
-
logger.info(f"\nFormulation parameters:")
|
| 301 |
-
logger.info(df[['ph', 'ionic_strength_mm', 'temperature_c']].describe())
|
| 302 |
-
logger.info(f"\nOutcomes:")
|
| 303 |
-
logger.info(df[['stability_score', 'predicted_aggregation_percent']].describe())
|
| 304 |
-
logger.info("=" * 70)
|
| 305 |
-
|
| 306 |
-
return df
|
| 307 |
-
|
| 308 |
-
|
| 309 |
-
def generate_synthetic_dataset(
|
| 310 |
-
output_dir: Path = None,
|
| 311 |
-
num_samples: int = 500_000,
|
| 312 |
-
seed: int = 42,
|
| 313 |
-
) -> pd.DataFrame:
|
| 314 |
-
"""
|
| 315 |
-
Convenience function: generate and save synthetic dataset.
|
| 316 |
-
|
| 317 |
-
Args:
|
| 318 |
-
output_dir: Directory to save dataset (default: data/)
|
| 319 |
-
num_samples: Number of samples (default: 500K)
|
| 320 |
-
seed: Random seed (default: 42)
|
| 321 |
-
|
| 322 |
-
Returns:
|
| 323 |
-
Generated DataFrame
|
| 324 |
-
"""
|
| 325 |
-
if output_dir is None:
|
| 326 |
-
output_dir = Path(__file__).parent
|
| 327 |
-
|
| 328 |
-
output_dir.mkdir(parents=True, exist_ok=True)
|
| 329 |
-
|
| 330 |
-
# Generate
|
| 331 |
-
generator = SyntheticDataGenerator(
|
| 332 |
-
num_samples=num_samples,
|
| 333 |
-
seed=seed,
|
| 334 |
-
)
|
| 335 |
-
|
| 336 |
-
# Save
|
| 337 |
-
output_path = output_dir / "synthetic_training_data"
|
| 338 |
-
df = generator.generate()
|
| 339 |
-
generator.save(output_path)
|
| 340 |
-
|
| 341 |
-
return df
|
| 342 |
-
|
| 343 |
-
|
| 344 |
-
if __name__ == "__main__":
|
| 345 |
-
"""Generate synthetic dataset."""
|
| 346 |
-
import sys
|
| 347 |
-
from pathlib import Path
|
| 348 |
-
|
| 349 |
-
logging.basicConfig(
|
| 350 |
-
level=logging.INFO,
|
| 351 |
-
format='%(asctime)s - %(name)s - %(levelname)s - %(message)s'
|
| 352 |
-
)
|
| 353 |
-
|
| 354 |
-
# Command line: python synthetic_generator.py <num_samples>
|
| 355 |
-
num_samples = int(sys.argv[1]) if len(sys.argv) > 1 else 10_000
|
| 356 |
-
|
| 357 |
-
df = generate_synthetic_dataset(
|
| 358 |
-
num_samples=num_samples,
|
| 359 |
-
seed=42,
|
| 360 |
-
)
|
| 361 |
-
|
| 362 |
-
print(f"\n✓ Generated {len(df)} synthetic samples")
|
| 363 |
-
print(f"Dataset saved to: data/synthetic_training_data.*")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
synthetic_training_data.csv
DELETED
|
@@ -1,3 +0,0 @@
|
|
| 1 |
-
version https://git-lfs.github.com/spec/v1
|
| 2 |
-
oid sha256:1ac5efd796179d568251b835650ecf54f37681f3a771a15fc6b0081baa109173
|
| 3 |
-
size 33722233
|
|
|
|
|
|
|
|
|
|
|
|
synthetic_training_data.parquet
DELETED
|
@@ -1,3 +0,0 @@
|
|
| 1 |
-
version https://git-lfs.github.com/spec/v1
|
| 2 |
-
oid sha256:a92c824956de1a8d877a2f28a4d89516ee0453d5c0d888921725da4fcc3fc4be
|
| 3 |
-
size 17981929
|
|
|
|
|
|
|
|
|
|
|
|